ABSTRACT
BACKGROUND: COVID-19 (coronavirus disease 2019) is associated with heightened risks of venous and arterial thrombosis and hospitalization due to respiratory failure. To assess whether prophylactic anticoagulation can safely reduce the frequency of venous and arterial thrombosis, hospitalization, and death in nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor, we conducted the PREVENT-HD double-blind, placebo-controlled randomized trial (A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19] Infection). METHODS: PREVENT-HD was conducted between August 2020 and April 2022 at 14 US integrated health care delivery networks. A virtual trial design used remote informed consent and clinical monitoring and facilitated data collection through electronic health record integration with a cloud-based research platform. Nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor were enrolled and randomly assigned to either 10 mg of oral rivaroxaban or placebo daily for 35 days. The primary efficacy outcome was time to first occurrence of a composite of symptomatic venous thromboembolism, myocardial infarction, ischemic stroke, acute limb ischemia, non-central nervous system systemic arterial embolism, hospitalization, or death through day 35. The principal safety end point was International Society on Thrombosis and Hemostasis critical-site or fatal bleeding. The last study visit was on day 49. RESULTS: The study was terminated prematurely because of enrollment challenges and a lower-than-expected blinded pooled event rate. A total of 1284 patients underwent randomization with complete accrual of primary events through May 2022. No patients were lost to follow-up. The primary efficacy outcome occurred in 22 of 641 in the rivaroxaban group and 19 of 643 in the placebo group (3.4% versus 3.0%; hazard ratio, 1.16 [95% CI, 0.63-2.15]; P=0.63). No patient in either group experienced critical-site or fatal bleeding. One patient receiving rivaroxaban had a major bleed. CONCLUSIONS: The study was terminated prematurely after enrollment of 32% of planned accrual because of recruitment challenges and lower-than-expected event rate. Rivaroxaban prescribed for 35 days in nonhospitalized patients with symptomatic COVID-19 at risk for thrombosis did not appear to reduce a composite end point of venous and arterial thrombotic events, hospitalization, and death. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04508023.
Subject(s)
COVID-19 , Thrombosis , Humans , Rivaroxaban/adverse effects , Outpatients , Thrombosis/epidemiology , Thrombosis/prevention & control , Hemorrhage/chemically induced , Hemorrhage/drug therapy , Hospitalization , Anticoagulants/adverse effectsABSTRACT
Importance: The incidence of arterial thromboembolism and venous thromboembolism in persons with COVID-19 remains unclear. Objective: To measure the 90-day risk of arterial thromboembolism and venous thromboembolism in patients hospitalized with COVID-19 before or during COVID-19 vaccine availability vs patients hospitalized with influenza. Design, Setting, and Participants: Retrospective cohort study of 41â¯443 patients hospitalized with COVID-19 before vaccine availability (April-November 2020), 44â¯194 patients hospitalized with COVID-19 during vaccine availability (December 2020-May 2021), and 8269 patients hospitalized with influenza (October 2018-April 2019) in the US Food and Drug Administration Sentinel System (data from 2 national health insurers and 4 regional integrated health systems). Exposures: COVID-19 or influenza (identified by hospital diagnosis or nucleic acid test). Main Outcomes and Measures: Hospital diagnosis of arterial thromboembolism (acute myocardial infarction or ischemic stroke) and venous thromboembolism (deep vein thrombosis or pulmonary embolism) within 90 days. Outcomes were ascertained through July 2019 for patients with influenza and through August 2021 for patients with COVID-19. Propensity scores with fine stratification were developed to account for differences between the influenza and COVID-19 cohorts. Weighted Cox regression was used to estimate the adjusted hazard ratios (HRs) for outcomes during each COVID-19 vaccine availability period vs the influenza period. Results: A total of 85â¯637 patients with COVID-19 (mean age, 72 [SD, 13.0] years; 50.5% were male) and 8269 with influenza (mean age, 72 [SD, 13.3] years; 45.0% were male) were included. The 90-day absolute risk of arterial thromboembolism was 14.4% (95% CI, 13.6%-15.2%) in patients with influenza vs 15.8% (95% CI, 15.5%-16.2%) in patients with COVID-19 before vaccine availability (risk difference, 1.4% [95% CI, 1.0%-2.3%]) and 16.3% (95% CI, 16.0%-16.6%) in patients with COVID-19 during vaccine availability (risk difference, 1.9% [95% CI, 1.1%-2.7%]). Compared with patients with influenza, the risk of arterial thromboembolism was not significantly higher among patients with COVID-19 before vaccine availability (adjusted HR, 1.04 [95% CI, 0.97-1.11]) or during vaccine availability (adjusted HR, 1.07 [95% CI, 1.00-1.14]). The 90-day absolute risk of venous thromboembolism was 5.3% (95% CI, 4.9%-5.8%) in patients with influenza vs 9.5% (95% CI, 9.2%-9.7%) in patients with COVID-19 before vaccine availability (risk difference, 4.1% [95% CI, 3.6%-4.7%]) and 10.9% (95% CI, 10.6%-11.1%) in patients with COVID-19 during vaccine availability (risk difference, 5.5% [95% CI, 5.0%-6.1%]). Compared with patients with influenza, the risk of venous thromboembolism was significantly higher among patients with COVID-19 before vaccine availability (adjusted HR, 1.60 [95% CI, 1.43-1.79]) and during vaccine availability (adjusted HR, 1.89 [95% CI, 1.68-2.12]). Conclusions and Relevance: Based on data from a US public health surveillance system, hospitalization with COVID-19 before and during vaccine availability, vs hospitalization with influenza in 2018-2019, was significantly associated with a higher risk of venous thromboembolism within 90 days, but there was no significant difference in the risk of arterial thromboembolism within 90 days.
Subject(s)
COVID-19 , Influenza, Human , Ischemic Stroke , Myocardial Infarction , Pulmonary Embolism , Venous Thrombosis , Aged , Aged, 80 and over , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19 Vaccines/therapeutic use , Female , Hospitalization/statistics & numerical data , Humans , Incidence , Influenza, Human/epidemiology , Ischemic Stroke/epidemiology , Male , Middle Aged , Myocardial Infarction/epidemiology , Public Health Surveillance , Pulmonary Embolism/epidemiology , Retrospective Studies , Risk , Risk Assessment , Thromboembolism/epidemiology , Thrombosis/epidemiology , United States/epidemiology , Venous Thrombosis/epidemiologyABSTRACT
OBJECTIVES: The aim of this study was to investigate the effects of rivaroxaban on left ventricle thromboprophylaxis in patients with anterior ST-segment elevation myocardial infarction (STEMI). BACKGROUND: Anterior STEMI is associated with an increased risk of left ventricular thrombus (LVT) formation. The contemporary role of prophylactic rivaroxaban therapy remains unclear. METHODS: We randomly assigned 279 patients with anterior STEMI who had undergone primary percutaneous coronary intervention to receive, in a 1:1 ratio, low-dose rivaroxaban (2.5 mg twice daily for 30 days) and dual antiplatelet therapy (DAPT) or only DAPT. The primary efficacy outcome was the LVT formation within 30 days. Net clinical adverse events were assessed at 30 days and 180 days, including all-cause mortality, LVT, systemic embolism, rehospitalization for cardiovascular events, and bleeding. RESULTS: The addition of low-dose rivaroxaban to DAPT reduced LVT formation within 30 days compared with only DAPT (0.7% vs 8.6%; HR: 0.08; 95% CI: 0.01-0.62; P = 0.015; P < 0.001 for superiority). Net clinical adverse events were lower within 30 days in the rivaroxaban group versus those in the only DAPT group and remained relatively low throughout the follow-up period. There were no significant differences in bleeding events between the 2 groups in 30 days and 180 days. However, 1 case of intracranial hemorrhage (major bleeding) occurred in the rivaroxaban group within 30 days. CONCLUSIONS: Our results supported that the short-duration addition of low-dose rivaroxaban to DAPT could prevent LVT formation in patients with anterior STEMI following primary percutaneous coronary intervention. A larger multiple-institution study is necessary to determine the generalizability.
Subject(s)
Rivaroxaban , ST Elevation Myocardial Infarction , Thrombosis , Dual Anti-Platelet Therapy/adverse effects , Hemorrhage/chemically induced , Humans , Percutaneous Coronary Intervention , Platelet Aggregation Inhibitors/adverse effects , Rivaroxaban/adverse effects , ST Elevation Myocardial Infarction/complications , ST Elevation Myocardial Infarction/drug therapy , Thrombosis/epidemiology , Thrombosis/prevention & control , Treatment OutcomeABSTRACT
Left atrial appendage closure (LAAC) are emerging treatment for patients with atrial fibrillation (AF). However, data on the safety, efficacy, and medications for LAAC devices in patients with AF are lacking. We aimed to investigate the incidence of all-cause mortality, stroke, and major bleeding in AF patients with LAAC devices and DOACs. Moreover, we aimed to investigate the incidence rate of device-related thrombus (DRT) and the medications used in the management of AF patients with LAAC devices to gain insights into achieving better outcome. Based on a literature search using PubMed, EMBASE, Cochrane Library, and Web of Science databases between January 2015 and December 2020, eight LAAC device studies that used WATCHMAN and Amulet, and three DOAC studies that used rivaroxaban, with a total of 24,055 AF patients (LAAC devices, n = 2855; DOAC, n = 21,200), were included. A random-effects model was used to incorporate heterogeneity among studies. The pooled incidence of events per person-years were as follows: all-cause mortality, 0.06 (95% confidence interval [CI] 0.02-0.10) for WATCHMAN, 0.04 (95% CI 0.00-0.14) for Amulet, and 0.03 (95% CI 0.01-0.04) for rivaroxaban; stroke; 0.02 (95% CI 0.00-0.04) for WATCHMAN, 0 for Amulet, and 0.01 (95% CI 0.01-0.02) for rivaroxaban; major bleeding, 0.04 (95% CI 0.02-0.06) for WATCHMAN, 0.02 (95% CI 0.00-0.06) for Amulet, and 0.02 (95% CI 0.01-0.03) for rivaroxaban. The incidence rate of DRT was 2.3%, and complications were reported in 9%. The incidence of all-cause mortality, stroke, and major bleeding were similar between LAAC devices and DOACs. The rate of complications was acceptable, and those of DRT were lower than the average incidence reported in previous studies. However, further follow-up is needed. Concomitant anticoagulant and antiplatelet therapies should be further evaluated to find the optimal regimen for AF patients with LAAC devices.
Subject(s)
Atrial Appendage , Atrial Fibrillation , Stroke , Thrombosis , Anticoagulants/adverse effects , Atrial Appendage/surgery , Atrial Fibrillation/complications , Atrial Fibrillation/drug therapy , Atrial Fibrillation/surgery , Hemorrhage/chemically induced , Hemorrhage/epidemiology , Humans , Rivaroxaban/adverse effects , Stroke/epidemiology , Stroke/etiology , Stroke/prevention & control , Thrombosis/epidemiology , Treatment OutcomeABSTRACT
Thromboembolic events remain clinically unresolved after transcatheter aortic valve implantation (TAVI). The use of direct oral anticoagulant (DOAC) to reduce thrombosis associated with TAVI remains controversial. This study aimed at investigating the periprocedural change in blood coagulation and thrombolysis parameters in 199 patients undergoing transfemoral TAVI. Prothrombin activation fragment 1â¯+â¯2 (F1â¯+â¯2), thrombin-antithrombin complex (TAT), soluble fibrin monomer complex (SFMC), and fibrin/fibrinogen degradation product (FDP) levels were measured before and 1 hour after TAVI and 1, 2, and 7 days postoperatively. Of the 199 patients, 49 were treated with DOAC (apixaban in 32, edoxaban in 10, and rivaroxaban in 7). The F1â¯+â¯2 and TAT levels immediately increased 1 hour after TAVI and then gradually decreased in both groups. The SFMC level also significantly increased with a peak on day 1. The FDP level gradually increased, peaking on day 2. The values of F1â¯+â¯2, TAT, SFMC, and FDP in patients who used DOAC were significantly lower than those who did not use DOAC at 1 hour after TAVI in F1â¯+â¯2 (600 [452 to 765] vs 1055 [812 to 1340] pmol/L; p < 0.001), TAT (21.4 [16.2 to 37.0] vs 38.7 [26.4 to 58.7] µg/mL; p < 0.001) and on day 1 in SFMC (18.2 [9.4 to 57.9] vs 113.4 [70.9 to 157.3] µg/mL; p < 0.001) and day 2 in FDP (6.0 [4.7 to 10.0] vs 12.6 [8.2 to 17.4] µg/mL; p < 0.001). Ischemic stroke within 30 days after TAVI occurred in 3 patients (1.5%), who were not treated with DOAC. Coagulation cascade activation was observed after TAVI. DOAC could reduce transient hypercoagulation following TAVI.
Subject(s)
Aortic Valve Stenosis/blood , Aortic Valve Stenosis/surgery , Blood Coagulation/physiology , Factor Xa Inhibitors/therapeutic use , Thrombosis/prevention & control , Transcatheter Aortic Valve Replacement/adverse effects , Aged, 80 and over , Antithrombin III , Aortic Valve Stenosis/mortality , Cohort Studies , Female , Fibrin Fibrinogen Degradation Products/metabolism , Humans , Male , Peptide Fragments/blood , Peptide Hydrolases/blood , Prothrombin , Pyrazoles/therapeutic use , Pyridines/therapeutic use , Pyridones/therapeutic use , Rivaroxaban/therapeutic use , Thiazoles/therapeutic use , Thrombosis/blood , Thrombosis/epidemiologyABSTRACT
We concisely review clinical, autopsy, experimental and molecular data of 2019 coronavirus disease (COVID-19). Angiotensin-converting enzyme 2 disruption and thromboinflammatory microangiopathy emerge as distinctive features. Briefly, entry of the virus into microvessels can profoundly disrupt the local renin-angiotensin system, cause endothelial injury, activate the complement cascade and induce powerful thromboinflammatory reactions, involving, in particular, von Willebrand factor, that, if widespread, may lead to microvascular plugging, ischemia and, ultimately, organ failure. We believe the current COVID-19 data consolidate a widely unrecognised paradigm of potentially fatal thromboinflammatory microvascular disease.
Subject(s)
Angiotensin-Converting Enzyme 2/metabolism , COVID-19/metabolism , Inflammation Mediators/metabolism , Microvessels/metabolism , Thrombosis/metabolism , COVID-19/diagnosis , COVID-19/epidemiology , Humans , Microvessels/pathology , Renin-Angiotensin System/physiology , Thrombosis/diagnosis , Thrombosis/epidemiologySubject(s)
Anticoagulants/adverse effects , Blood Coagulation Factors/therapeutic use , Cerebral Intraventricular Hemorrhage/therapy , Deamino Arginine Vasopressin/therapeutic use , Hemostatics/therapeutic use , Intracranial Hemorrhage, Traumatic/drug therapy , Platelet Aggregation Inhibitors/adverse effects , Aged , Aged, 80 and over , Aspirin/adverse effects , Cerebral Hemorrhage, Traumatic/etiology , Cerebral Hemorrhage, Traumatic/therapy , Cerebral Intraventricular Hemorrhage/chemically induced , Clopidogrel/adverse effects , Female , Fractures, Bone/complications , Hematoma/etiology , Hematoma/therapy , Hematoma, Subdural, Intracranial/etiology , Hematoma, Subdural, Intracranial/therapy , Humans , International Normalized Ratio , Intracranial Hemorrhage, Traumatic/etiology , Male , Middle Aged , Pelvic Bones/injuries , Pyrazoles/adverse effects , Pyridones/adverse effects , Retrospective Studies , Rivaroxaban/adverse effects , Subarachnoid Hemorrhage, Traumatic/etiology , Subarachnoid Hemorrhage, Traumatic/therapy , Thrombosis/chemically induced , Thrombosis/epidemiology , Warfarin/adverse effectsABSTRACT
COVID-19 symptoms vary from silence to rapid death, the latter mediated by both a cytokine storm and a thrombotic storm. SARS-CoV (2003) induces Cox-2, catalyzing the synthesis, from highly unsaturated fatty acids (HUFA), of eicosanoids and docosanoids that mediate both inflammation and thrombosis. HUFA balance between arachidonic acid (AA) and other HUFA is a likely determinant of net signaling to induce a healthy or runaway physiological response. AA levels are determined by a non-protein coding regulatory polymorphisms that mostly affect the expression of FADS1, located in the FADS gene cluster on chromosome 11. Major and minor haplotypes in Europeans, and a specific functional insertion-deletion (Indel), rs66698963, consistently show major differences in circulating AA (>50%) and in the balance between AA and other HUFA (47-84%) in free living humans; the indel is evolutionarily selective, probably based on diet. The pattern of fatty acid responses is fully consistent with specific genetic modulation of desaturation at the FADS1-mediated 20:3â20:4 step. Well established principles of net tissue HUFA levels indicate that the high linoleic acid and low alpha-linoleic acid in populations drive the net balance of HUFA for any individual. We predict that fast desaturators (insertion allele at rs66698963; major haplotype in Europeans) are predisposed to higher risk and pathological responses to SARS-CoV-2 could be reduced with high dose omega-3 HUFA.
Subject(s)
Coronavirus Infections/complications , Fatty Acids, Unsaturated/biosynthesis , Inflammation/etiology , Lipid Metabolism/genetics , Pneumonia, Viral/complications , Thrombosis/etiology , Betacoronavirus/physiology , COVID-19 , Coronavirus Infections/epidemiology , Coronavirus Infections/genetics , Coronavirus Infections/metabolism , Delta-5 Fatty Acid Desaturase , Fatty Acids, Unsaturated/genetics , Genetic Predisposition to Disease , Haplotypes , Humans , Individuality , Inflammation/epidemiology , Inflammation/genetics , Inflammation/metabolism , Lipogenesis/genetics , Metabolic Networks and Pathways/genetics , Pandemics , Pneumonia, Viral/epidemiology , Pneumonia, Viral/genetics , Pneumonia, Viral/metabolism , Polymorphism, Single Nucleotide , Risk Factors , SARS-CoV-2 , Thrombosis/epidemiology , Thrombosis/genetics , Thrombosis/metabolismABSTRACT
Risk factors for COVID-19 patients with poorer outcomes include pre-existing conditions: obesity, type 2 diabetes mellitus, cardiovascular disease (CVD), heart failure, hypertension, low oxygen saturation capacity, cancer, elevated: ferritin, C reactive protein (CRP) and D-dimer. A common denominator, hyperinsulinaemia, provides a plausible mechanism of action, underlying CVD, hypertension and strokes, all conditions typified with thrombi. The underlying science provides a theoretical management algorithm for the frontline practitioners.Vitamin D activation requires magnesium. Hyperinsulinaemia promotes: magnesium depletion via increased renal excretion, reduced intracellular levels, lowers vitamin D status via sequestration into adipocytes and hydroxylation activation inhibition. Hyperinsulinaemia mediates thrombi development via: fibrinolysis inhibition, anticoagulation production dysregulation, increasing reactive oxygen species, decreased antioxidant capacity via nicotinamide adenine dinucleotide depletion, haem oxidation and catabolism, producing carbon monoxide, increasing deep vein thrombosis risk and pulmonary emboli. Increased haem-synthesis demand upregulates carbon dioxide production, decreasing oxygen saturation capacity. Hyperinsulinaemia decreases cholesterol sulfurylation to cholesterol sulfate, as low vitamin D regulation due to magnesium depletion and/or vitamin D sequestration and/or diminished activation capacity decreases sulfotransferase enzyme SULT2B1b activity, consequently decreasing plasma membrane negative charge between red blood cells, platelets and endothelial cells, thus increasing agglutination and thrombosis.Patients with COVID-19 admitted with hyperglycaemia and/or hyperinsulinaemia should be placed on a restricted refined carbohydrate diet, with limited use of intravenous dextrose solutions. Degree/level of restriction is determined by serial testing of blood glucose, insulin and ketones. Supplemental magnesium, vitamin D and zinc should be administered. By implementing refined carbohydrate restriction, three primary risk factors, hyperinsulinaemia, hyperglycaemia and hypertension, that increase inflammation, coagulation and thrombosis risk are rapidly managed.
Subject(s)
Coronavirus Infections/therapy , Diet, Carbohydrate-Restricted , Dietary Supplements , Hyperinsulinism/therapy , Insulin/blood , Magnesium/therapeutic use , Pneumonia, Viral/therapy , Thrombosis/therapy , Vitamin D/therapeutic use , Betacoronavirus/pathogenicity , Biomarkers/blood , Blood Glucose/metabolism , COVID-19 , Coronavirus Infections/blood , Coronavirus Infections/epidemiology , Coronavirus Infections/virology , Dietary Supplements/adverse effects , Host-Pathogen Interactions , Humans , Hyperinsulinism/blood , Hyperinsulinism/epidemiology , Ketones/blood , Magnesium/blood , Pandemics , Pneumonia, Viral/blood , Pneumonia, Viral/epidemiology , Pneumonia, Viral/virology , Prognosis , Risk Factors , SARS-CoV-2 , Thrombosis/blood , Thrombosis/epidemiology , Thrombosis/virology , Vitamin D/blood , Zinc/therapeutic useABSTRACT
BACKGROUND: Left ventricular thrombus (LVT) is an important complication in the setting of systolic dysfunction, particularly after acute myocardial infarction. Current guidelines recommend the vitamin-K antagonist, warfarin, for the treatment of LVT. AREA OF UNCERTAINTY AND STUDY QUESTION: The direct oral anticoagulants (DOACs) are being increasingly used for the management of this entity, despite lack of randomized trials in support of it or knowledge about their efficacy. We aimed to assess the frequency of use and the efficacy of DOACs in the treatment of LVT. DATA SOURCES: We searched published articles in Google Scholar, PubMed, MEDLINE, and Embase from the introduction of DOACs in any therapy until April 2018. Reports describing patients diagnosed with LVT and who were treated with a DOAC were examined. Patient characteristics, comorbidities, pharmacologic treatments, and outcomes were collected. The primary end points of this study were thrombus resolution and time to resolution. Other end points were bleeding and thromboembolic events. RESULTS: Thirty articles describing 41 patients were analyzed. The most common risk factors for LVT formation were male gender, ischemic heart disease, and low ejection fraction. Most patients were treated with rivaroxaban (51.2%), followed by apixaban (26.8%) and dabigatran (22%). Patients were treated with DOAC alone (46.3%), DOAC and aspirin (12.2%), DOAC and clopidogrel (2.4%), and triple therapy (39%). Thrombus resolution success rate was 81%, 100%, and 88.9% for rivaroxaban, apixaban, and dabigatran, respectively. The median time of thrombus resolution was 40 days, 36 days, and 24 days for rivaroxaban, apixaban, and dabigatran, respectively. One nonfatal bleeding event and one stroke event were reported while on a DOAC. CONCLUSIONS: The use of DOACs is a reasonable alternative to vitamin-K antagonists in the management of LVT.
Subject(s)
Anticoagulants/administration & dosage , Heart Diseases/drug therapy , Myocardial Infarction/complications , Thrombosis/drug therapy , Administration, Oral , Anticoagulants/adverse effects , Aspirin/administration & dosage , Aspirin/adverse effects , Clopidogrel/administration & dosage , Clopidogrel/adverse effects , Dabigatran/administration & dosage , Dabigatran/adverse effects , Drug Therapy, Combination/adverse effects , Drug Therapy, Combination/methods , Heart Diseases/epidemiology , Heart Diseases/etiology , Heart Diseases/pathology , Heart Ventricles/pathology , Hemorrhage/chemically induced , Hemorrhage/epidemiology , Humans , Myocardial Infarction/drug therapy , Pyrazoles/administration & dosage , Pyrazoles/adverse effects , Pyridones/administration & dosage , Pyridones/adverse effects , Risk Factors , Rivaroxaban/administration & dosage , Stroke/chemically induced , Stroke/epidemiology , Thrombosis/epidemiology , Thrombosis/etiology , Thrombosis/pathology , Treatment OutcomeABSTRACT
The incorporation of L-asparaginase and pegylated asparaginase into pediatric-inspired regimens has conferred a survival advantage in treatment of adults with acute lymphoblastic leukemia. Use of asparaginase products requires careful prevention, monitoring, and management of adverse effects including hypersensitivity, hepatotoxicity, pancreatitis, coagulopathy, and thrombosis. Currently, there is limited published literature to offer guidance on management of these toxicities. At the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, a standard of practice guideline was created to prevent and manage asparaginase-related adverse events. By sharing our long-term experience with asparaginase products and clinical management of asparaginase-induced toxicities, this article aims to improve patient safety and optimize treatment outcomes.
Subject(s)
Antineoplastic Agents/administration & dosage , Asparaginase/administration & dosage , Cancer Care Facilities/standards , Disease Management , Drug Monitoring/standards , Polyethylene Glycols/administration & dosage , Practice Guidelines as Topic/standards , Adult , Antineoplastic Agents/adverse effects , Asparaginase/adverse effects , Child, Preschool , Dose-Response Relationship, Drug , Drug Monitoring/methods , Humans , Polyethylene Glycols/adverse effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/epidemiology , Thrombosis/chemically induced , Thrombosis/epidemiology , Thrombosis/prevention & control , Treatment OutcomeABSTRACT
Background: The potential role of new oral anticoagulants in antiphospholipid antibody syndrome (APS) remains uncertain. Objective: To determine whether rivaroxaban is noninferior to dose-adjusted vitamin K antagonists (VKAs) for thrombotic APS. Design: 3-year, open-label, randomized noninferiority trial. (EU Clinical Trials Register: EUDRA [European Union Drug Regulatory Authorities] code 2010-019764-36). Setting: 6 university hospitals in Spain. Participants: 190 adults (aged 18 to 75 years) with thrombotic APS. Intervention: Rivaroxaban (20 mg/d or 15 mg/d, according to renal function) versus dose-adjusted VKAs (target international normalized ratio, 2.0 to 3.0, or 3.1 to 4.0 in patients with a history of recurrent thrombosis). Measurements: The primary efficacy outcome was the proportion of patients with new thrombotic events; the primary safety outcome was major bleeding. The prespecified noninferiority margin for risk ratio (RR) was 1.40. Secondary outcomes included time to thrombosis, type of thrombosis, changes in biomarker levels, cardiovascular death, and nonmajor bleeding. Results: After 3 years of follow-up, recurrent thrombosis occurred in 11 patients (11.6%) in the rivaroxaban group and 6 (6.3%) in the VKA group (RR in the rivaroxaban group, 1.83 [95% CI, 0.71 to 4.76]). Stroke occurred more commonly in patients receiving rivaroxaban (9 events) than in those receiving VKAs (0 events) (corrected RR, 19.00 [CI, 1.12 to 321.9]). Major bleeding occurred in 6 patients (6.3%) in the rivaroxaban group and 7 (7.4%) in the VKA group (RR, 0.86 [CI, 0.30 to 2.46]). Post hoc analysis suggested an increased risk for recurrent thrombosis in rivaroxaban-treated patients with previous arterial thrombosis, livedo racemosa, or APS-related cardiac valvular disease. Limitation: Anticoagulation intensity was not measured in the rivaroxaban group. Conclusion: Rivaroxaban did not show noninferiority to dose-adjusted VKAs for thrombotic APS and, in fact, showed a non-statistically significant near doubling of the risk for recurrent thrombosis. Primary Funding Source: Bayer Hispania.
Subject(s)
Anticoagulants/therapeutic use , Antiphospholipid Syndrome/drug therapy , Factor Xa Inhibitors/therapeutic use , Rivaroxaban/therapeutic use , Thrombosis/prevention & control , Warfarin/therapeutic use , Adult , Female , Hemorrhage/epidemiology , Humans , Male , Middle Aged , Recurrence , Secondary Prevention , Stroke/epidemiology , Thrombosis/epidemiology , Vitamin K/antagonists & inhibitorsSubject(s)
Anticoagulants/therapeutic use , Antiphospholipid Syndrome/drug therapy , Factor Xa Inhibitors/therapeutic use , Rivaroxaban/therapeutic use , Thrombosis/prevention & control , Warfarin/therapeutic use , Equivalence Trials as Topic , Hemorrhage/epidemiology , Humans , Recurrence , Secondary Prevention , Stroke/epidemiology , Thrombosis/epidemiology , Vitamin K/antagonists & inhibitorsABSTRACT
OBJECTIVE: It is not known whether direct-acting oral anticoagulants (DOACs), such as dabigatran, apixaban, and rivaroxaban increase the risk of bleeding complications during or after coronary catheterization. The aim of this study was to investigate the safety of uninterrupted DOAC treatment during diagnostic radial coronary angiography (CAG). METHODS: This study included 160 patients who underwent diagnostic radial cardiac catheterization. The 60 patients in the group who were using a DOAC (apixaban, rivaroxaban, or dabigatran) were enrolled in a Group A. Post-procedure results from patients in Group A were compared with those of an age- and sex-matched control group (Group B) that included 100 patients who underwent radial CAG who did not use a DOAC. RESULTS: There was no significant difference in the procedure and compression times, creatinine level, or presence of hypertension, diabetes mellitus, smoking, alcohol use, vascular disease, or congestive heart failure between the 2 groups. During the 1 -month follow-up period, only 1 radial occlusion was registered in the control group (Group B). There was no case of a large hematoma (>5 cm or extending to the forearm), dissection, fistula, perforation, or compartment syndrome. Hematomas smaller than 5 cm were seen in 2 patients (1 in each group). No thrombotic events were observed during follow-up examinations. CONCLUSION: Performing radial CAG with uninterrupted DOAC treatment appears to carry no risk of increased early or short-term complications. The simple, uninterrupted DOAC strategy is comfortable, easy, and safe.
Subject(s)
Anticoagulants , Cardiac Catheterization , Coronary Angiography , Aged , Anticoagulants/adverse effects , Anticoagulants/therapeutic use , Cardiac Catheterization/adverse effects , Cardiac Catheterization/statistics & numerical data , Coronary Angiography/adverse effects , Coronary Angiography/methods , Dabigatran/adverse effects , Dabigatran/therapeutic use , Female , Hematoma/epidemiology , Humans , Male , Middle Aged , Prospective Studies , Pyrazoles/adverse effects , Pyrazoles/therapeutic use , Pyridones/adverse effects , Pyridones/therapeutic use , Rivaroxaban/adverse effects , Rivaroxaban/therapeutic use , Thrombosis/epidemiologyABSTRACT
INTRODUCTION: Calciphylaxis is a rare but devastating disease with a mortality rate up to 50% in 1 year. It is characterized by profoundly painful ischemic skin lesions and vascular calcification that affects predominantly patients with end stage renal disease. The use of certain medications is an important modifiable risk factor in calciphylaxis and discontinuation of these is a mainstay of treatment. AREAS COVERED: This review will provide an overview of calciphylaxis and will focus on how certain therapeutic agents can affect the risk of calcification and associated thrombosis, key processes involved in the development of calciphylaxis. EXPERT OPINION: Calciphylaxis treatment requires a multi-modal approach including prevention, risk factor management, wound care, reperfusion, and use of fibrinolytics and antioxidants. Patients with end stage renal disease represent the most affected population. This population often has multiple medications prescribed, some worth reconsidering before starting or continuing them. When possible, we recommend stopping all potentially contributing medications in patients with calciphylaxis, including warfarin, active vitamin D, calcium supplements, and iron.
Subject(s)
Calciphylaxis/chemically induced , Drug-Related Side Effects and Adverse Reactions/epidemiology , Kidney Failure, Chronic/complications , Animals , Calciphylaxis/epidemiology , Drug-Related Side Effects and Adverse Reactions/etiology , Humans , Risk Factors , Thrombosis/chemically induced , Thrombosis/epidemiologySubject(s)
Factor Xa Inhibitors/therapeutic use , Heart Ventricles/pathology , Myocardial Ischemia/complications , Rivaroxaban/therapeutic use , Thrombosis/drug therapy , Administration, Oral , Echocardiography , Heart Ventricles/diagnostic imaging , Humans , Incidence , Magnetic Resonance Imaging , Thrombosis/epidemiology , Thrombosis/etiology , Treatment OutcomeABSTRACT
Following an acute coronary syndrome (ACS), heightened predisposition to atherothrombotic events may persist for years. Advances in understanding the pathobiology that underlies this elevated risk furnish a mechanistic basis for devising long-term secondary prevention strategies. Recent progress in ACS pathophysiology has challenged the focus on single "vulnerable plaques" and shifted toward a more holistic consideration of the "vulnerable patient," thus highlighting the primacy of medical therapy in secondary prevention. Despite current guideline-directed medical therapy, a consistent proportion of post-ACS patients experience recurrent atherothrombosis due to unaddressed "residual risk": contemporary clinical trials underline the pivotal role of platelets, coagulation, cholesterol, and systemic inflammation and provide a perspective on a personalized, targeted approach. Emerging data sheds new light on heretofore unrecognized residual risk factors. This review aims to summarize evolving evidence relative to secondary prevention of atherothrombosis, with a focus on recent advances that promise to transform the management of the post-ACS patient.
Subject(s)
Acute Coronary Syndrome/epidemiology , Acute Coronary Syndrome/therapy , Thrombosis/epidemiology , Thrombosis/prevention & control , Acute Coronary Syndrome/physiopathology , Clinical Trials as Topic/methods , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Platelet Aggregation Inhibitors/administration & dosage , Review Literature as Topic , Risk Factors , Secondary Prevention/methods , Thrombosis/physiopathology , Time FactorsABSTRACT
BACKGROUND: Intravenous (IV) iron supplementation is a standard maintenance treatment for hemodialysis (HD) patients, but the optimum dosing regimen is unknown. METHODS: PIVOTAL (Proactive IV irOn Therapy in hemodiALysis patients) is a multicenter, open-label, blinded endpoint, randomized controlled (PROBE) trial. Incident HD adults with a serum ferritin < 400 µg/L and transferrin saturation (TSAT) levels < 30% receiving erythropoiesis-stimulating agents (ESA) were eligible. Enrolled patients were randomized to a proactive, high-dose IV iron arm (iron sucrose 400 mg/month unless ferritin > 700 µg/L and/or TSAT ≥40%) or a reactive, low-dose IV iron arm (iron sucrose administered if ferritin <200 µg/L or TSAT < 20%). We hypothesized that proactive, high-dose IV iron would be noninferior to reactive, low-dose IV iron for the primary outcome of first occurrence of nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for heart failure or death from any cause. If noninferiority is confirmed with a noninferiority limit of 1.25 for the hazard ratio of the proactive strategy relative to the reactive strategy, a test for superiority will be carried out. Secondary outcomes include infection-related endpoints, ESA dose requirements, and quality-of-life measures. As an event-driven trial, the study will continue until at least 631 primary outcome events have accrued, but the expected duration of follow-up is 2-4 years. RESULTS: Of the 2,589 patients screened across 50 UK sites, 2,141 (83%) were randomized. At baseline, 65.3% were male, the median age was 65 years, and 79% were white. According to eligibility criteria, all patients were on ESA at screening. Prior stroke and MI were present in 8 and 9% of the cohort, respectively, and 44% of patients had diabetes at baseline. Baseline data for the randomized cohort were generally concordant with recent data from the UK Renal Registry. CONCLUSIONS: PIVOTAL will provide important information about the optimum dosing of IV iron in HD patients representative of usual clinical practice. TRIAL REGISTRATION: EudraCT number: 2013-002267-25.
Subject(s)
Anemia, Iron-Deficiency/drug therapy , Ferric Oxide, Saccharated/administration & dosage , Hematinics/administration & dosage , Kidney Failure, Chronic/complications , Renal Dialysis/adverse effects , Administration, Intravenous , Aged , Anemia, Iron-Deficiency/blood , Anemia, Iron-Deficiency/etiology , Dose-Response Relationship, Drug , Female , Ferric Oxide, Saccharated/adverse effects , Ferritins/blood , Follow-Up Studies , Hematinics/adverse effects , Humans , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/therapy , Male , Middle Aged , Prospective Studies , Thrombosis/chemically induced , Thrombosis/epidemiology , Treatment OutcomeABSTRACT
BACKGROUND: This registry study evaluated the effects of Pycnogenol® on edema and thrombotic complications in long-haul flights; jet lag was also evaluated. METHODS: Four hundred and fifty subjects at different risk levels for thrombosis, flying in economy class twice a week for more than 8 hours, were included; 295 completed the registry study and were subdivided in 3 groups according to their risk level - low, moderate, or high. The high-risk group also received Aspirin®. A standard management (SM) was used in all groups. In each risk category, three groups were made according to patient management: a Pycnogenol group, a SM group (control), and a stockings group. The groups were comparable at inclusion. No side effects were observed. RESULTS: In the low risk group edema were reduced more (P<0.05) with Pycnogenol and stockings compared to control. Ankle circumference was smaller with Pycnogenol (P<0.05). No thrombosis was detected. D-dimer was negative in Pycnogenol subjects; one subject in the control group had increased values, as did two of the 36 subjects in the stockings group. In the group with moderate risk, edema and ankle circumference were lower in the Pycnogenol group (P<0.05). One deep vein thrombosis (DVT) and one minimal superficial vein thrombosis (SVT) were seen in controls. D-dimer was normal in the Pycnogenol group. In high-risk subjects, edema, and ankle circumference were significantly reduced in the Pycnogenol group (P<0.05). There were no SVT or DVT in the Pycnogenol group. One minimal DVT and one SVT were observed in controls. D-dimer was negative in all Pycnogenol subjects (P<0.05); three post-flight values increased in controls and in four of the 32 subjects in the stockings group. The jet lag score was lower in low-, medium-, and high-risk Pycnogenol subjects (P<0.05). CONCLUSIONS: This registry study indicates that Pycnogenol supplementation reduces edema and may control some thrombotic events.